Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
L-type voltage-gated calcium channels (VGCCs), also known as L-type Ca²⁺ channels or LTCCs, are a subtype of high-voltage activated, voltage-dependent calcium channels. The "L" stands for "long-lasting," referring to the sustained inward current these channels mediate during membrane depolarization. They are essential for coupling electrical signals to physiological responses in excitable cells such as cardiac, skeletal, and smooth muscle cells, as well as neurons. The main pore-forming α₁ subunits of L-type VGCCs are encoded by CACNA1S (CaV1.1) – Skeletal muscle, CACNA1C (CaV1.2) – Cardiac/smooth muscle, CACNA1D (CaV1.3) – Neurons/endocrine cells, and CACNA1F (CaV1.4) – Retina. A distinguishing feature is their high sensitivity to organic L-type calcium channel blockers ("calcium antagonists"), including dihydropyridines, phenylalkylamines, and benzothiazepines—widely used clinically for cardiovascular diseases like hypertension and arrhythmias.
Blockade of calcium influx through L-type voltage-gated calcium channels
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated calcium channel (L-type).